Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0GJLAS
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
aRX305
|
|||||
| Synonyms |
ARX305; NCB002; JNJ-0631
Click to Show/Hide
|
|||||
| Organization |
Ambrx (Top20 MNC) (Originator);NovoCodex Biopharmaceuticals
|
|||||
| Drug Status |
Phase 2
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-CD70 mAb
|
Antibody Info | ||||
| Antigen Name |
CD70 antigen (CD70)
|
Antigen Info | ||||
| Payload Name |
Amberstatin 269 (AS269)
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Oxime-PEG3
|
Linker Info | ||||
| Conjugate Type |
Non-natural Amino Acids
|
|||||
| Combination Type |
amberstatin
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Unspecific hematological malignancies |
1 Trials
|
||||||||
| Unspecific solid tumor |
1 Trials
|